

## Personalised medicine in urological oncology

Thematic Session 01

Sunday, 26 March  
10:30 - 12:00

**Location:** Room Paris, North Hall (Level 1)

**Chairs:** Z. Culig, Innsbruck (AT)  
J.A. Schalken, Nijmegen (NL)

### Aims and objectives of this session

Individualized therapy in prostate cancer should be based on our knowledge about overexpressed oncogenes. The session will highlight importance of the transcription factor ERG and cytokines which may be targeted in experimental models and in clinical settings. Furthermore, the speakers will address issues related to scientific background of radiation therapy in prostate cancer.

10:30 - 10:50

**State-of-the-art lecture** **How to select prostate cancer patients for radiation therapy?**  
A. Dubrovskaja, Dresden (DE)

10:50 - 11:10

**State-of-the-art lecture** **Personalised approach to antagonising ERG in prostate cancer**  
G. Carbone, Bellinzona (CH)

11:10 - 11:30

**State-of-the-art lecture** **Individualisation of anti-cytokine treatment in prostate cancer**  
A.S. Bjartell, Malmö (SE)

11:30 - 11:45

**Panel discussion** **Using translational research to optimise treatment for patients with prostate cancer**

**Panel:** A.S. Bjartell, Malmö (SE)  
G. Carbone, Bellinzona (CH)  
A. Dubrovskaja, Dresden (DE)

11:45 - 12:00

**Associated abstract presentations**

754

**Systems pharmacology and quantitative proteomics for developing targeted triple therapy**

**By:** [Ebhardt H.A.](#)<sup>1</sup>, [Root A.](#)<sup>2</sup>, [Beizaei A.](#)<sup>1</sup>, [Liu Y.](#)<sup>3</sup>, [Gauthier N.](#)<sup>4</sup>, [Sander C.](#)<sup>4</sup>, [Aebersold R.](#)<sup>3</sup>

**Institutes:**<sup>1</sup>University College Dublin, Systems Biology Ireland, Dublin, Ireland, <sup>2</sup>Memorial Sloan-Kettering Cancer Center, Weill Cornell Graduate School of Medical Sciences, New York City, United States of America, <sup>3</sup>ETH Zurich, Institute of Molecular Systems Biology, Zurich, Switzerland, <sup>4</sup>Dana-Farber Cancer Institute, CBio Center At Dana-Farber, Boston, United States of America

**State-of-the-art lecture**

747

**Targeting enzalutamide-resistant prostate cancer using the novel androgen receptor inhibitor ODM-201**

**By:** [Borgmann H.](#), [Ozistanbullu D.](#), [Beraldi E.](#), [Dalal K.](#), [Fazli L.](#), [Gleave M.](#)

**Institutes:** Vancouver Prostate Centre, Dept. of Urology, Vancouver, Canada

**State-of-the-art lecture**

